“This publication validates our belief that precision medicine should be measured, not marketed,” said Katy Whalen, ...

Study finds MPS2 scores are highly reproducible across DRE and non-DRE urine samples alike. “This study reinforces the value of MPS2 as a non-invasive diagnostic tool that delivers consistent and ...

SAN ANTONIO--(BUSINESS WIRE)--bioAffinity Technologies, a privately held biotech company advancing cutting-edge cancer diagnostics, and Precision Pathology Services, a CAP/CLIA-certified anatomic and ...

The companies share how their collaboration enables clinical trial enrollment for a novel cancer therapy for oncogene amplified cancers in development by Boundless Bio It is well established that ...

Early Completion of Model-Assisted Designs for Dose-Finding Trials Accurate assessment of a molecular classifier that guides patient care is of paramount importance in precision oncology. Recent years ...

The MarketWatch News Department was not involved in the creation of this content. Validation Results Pave the Way for Clinical Studies Focused on Transforming Patient Outcomes inInflammatory ...

PHOENIX, AZ, UNITED STATES, June 2, 2025 /EINPresswire.com/ -- Precision Epigenomics, a biotechnology company advancing epigenetic-based diagnostics, today announced ...

The firm will retrospectively analyze data from more than 1,100 breast cancer patients treated in Unicancer's clinical trials.

SAN ANTONIO--(BUSINESS WIRE)--bioAffinity Technologies, a privately held biotech company advancing innovative cancer diagnostics, announced that Precision Pathology Services, a CAP/CLIA-certified ...